Does Rallies show Form 4 insider transactions for NVCT?

Yes. Rallies tracks NVCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NVCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVCT. It does not provide personalized investment advice.

NVCT (Nuvectis Pharma, Inc. Common Stock) Stock Analysis - Insider Trades

Nuvectis Pharma, Inc. Common Stock (NVCT) is a publicly traded Healthcare sector company. As of May 21, 2026, NVCT trades at $10.63 with a market cap of $275.87M and a P/E ratio of -7.99. NVCT moved +3.11% today. Year to date, NVCT is +24.62%; over the trailing twelve months it is -0.19%. Its 52-week range spans $4.44 to $13.34. Analyst consensus is buy with an average price target of $13.50. Rallies surfaces NVCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NVCT stock inside the company?

Recent NVCT insider activity includes BENTSUR RON bought 5.00K, Sanchez Juan bought 13.00K, Kaplan Matthew L. bought 11.00K, Mosseri Marlio Charles bought 72.84K, and Mosseri Marlio Charles bought 35.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NVCT Key Metrics

Key financial metrics for NVCT
Metric	Value
Price	$10.63
Market Cap	$275.87M
P/E Ratio	-7.99
EPS	$-1.32
Dividend Yield	0.00%
52-Week High	$13.34
52-Week Low	$4.44
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-26.44M
Gross Margin	0.00%

Recent NVCT Insider Trades

BENTSUR RON bought 5.00K (~$28.60K) on Nov 5, 2025.
Sanchez Juan bought 13.00K (~$75.27K) on Nov 5, 2025.
Kaplan Matthew L. bought 11.00K (~$64.24K) on Nov 5, 2025.
Mosseri Marlio Charles bought 72.84K (~$457.41K) on Oct 27, 2025.
Mosseri Marlio Charles bought 35.03K (~$215.46K) on Oct 24, 2025.

Latest NVCT News

Nuvectis Pharma Q1 Cash Falls to $25.1M, Net Loss Widens to $6.1M — May 5, 2026
Nuvectis to Present NXP900 Synergy and Resistance Data at AACR April 21–22 — Mar 31, 2026
Nuvectis Raises Cash to $31.6M, Reports $26.4M Net Loss and Phase 1b Progress — Feb 11, 2026

NVCT Analyst Consensus

2 analysts cover NVCT: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.50.

Common questions about NVCT

Who is trading NVCT stock inside the company?: Recent NVCT insider activity includes BENTSUR RON bought 5.00K, Sanchez Juan bought 13.00K, Kaplan Matthew L. bought 11.00K, Mosseri Marlio Charles bought 72.84K, and Mosseri Marlio Charles bought 35.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NVCT?: Yes. Rallies tracks NVCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NVCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVCT. It does not provide personalized investment advice.